Lubrizol Forms Alliance with Particle Sciences after Vesta Acquisition
The Lubrizol Corporation announces an alliance between Lubrizol LifeSciences and Particle Sciences. This alliance offers customers a comprehensive solution providing a range of materials, drug development and commercial manufacturing services that is one of the most comprehensive in the pharmaceutical industry.
Lubrizol’s recent acquisition of contract manufacturer Vesta, in combination with Lubrizol’s alliance with Particle Sciences, means that the LifeSciences business now offers complete solutions for sustained, controlled release and combination products from polymer supply and drug product development through quality manufacturing services. Lubrizol LifeSciences (booth 1817) will officially launch its alliance with Particle Sciences (booth 2911) at the American Association of Pharmaceutical Scientists (AAPS) conference 2–6 November at the San Diego Convention Center.
"We’ve broadened our offering and further reinforced our commitment to the pharmaceutical market," says Jean Claude Deneuville, Lubrizol LifeSciences director of the Pharma Solutions business. "By joining forces with Vesta and working with Particle Sciences, we have further expanded our set of skills and brought full-service solutions to the market." Lubrizol LifeSciences now offers a combination of world class polymer technology, drug product development services, clinical supply, applications know-how and commercial manufacturing.
"Teaming up with both Vesta and Particle Sciences enables Lubrizol to leverage our core polymer chemistry into tailored solutions for novel implantable and dermal drug delivery systems and combination products to deliver improved patient outcomes," says Joey Glassco, global market manager for Lubrizol LifeSciences.
The recent acquisition of Vesta broadens Lubrizol's life science manufacturing capabilities, applications and material portfolio with access to silicone polymers and a variety of thermoplastics utilised in medical devices, advanced wound care and drug eluting products such as subcutaneous implants and intravaginal rings. Headquartered in Franklin, WI, Vesta leverages over four decades of engineering expertise and manufacturing experience to service clinical device applications with the quality that customers trust.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance